🔴 Sanofi Shares Fall 4.3% as Investors Focus on New CEO's Strategy and Pipeline Cuts Despite Q2 Revenue Beat and Raised Guidance

Sanofi is trading at $42.92 (-4.29%) in pre-market, with shares declining following its Q2 2026 earnings report today.

• The pharmaceutical giant reported Q2 revenue of €11.6 billion, surpassing the IBES consensus estimate of €11.2 billion, driven by strong Dupixent sales which rose 38% to €5.15 billion.
• Sanofi also raised its full-year sales growth forecast to approximately 10% at constant exchange rates.
• However, the stock's decline indicates investor focus on the new CEO's ongoing strategic review, pipeline changes, including drug cancellations, and the company's reliance on Dupixent for growth, overshadowing the positive financial results.